Celcuity’s stock jumps after Phase 3 trial shows gedatolisib slashes progression risk in breast cancer patients by up to 76%.

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...

An update from Celcuity ( (CELC) ) is now available.

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

Celcuity (NASDAQ:CELC) has announced the pricing of two underwritten public offerings. The first is a $175 million offering ...

Celcuity ( ($CELC) ) has issued an announcement. On July 30, 2025, Celcuity Inc. entered into an underwriting agreement with several underwriters ...

Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s ...